These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30791762)

  • 21. The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development--a potential therapeutic target?
    Dongiovanni P; Rametta R; Meroni M; Valenti L
    Expert Rev Gastroenterol Hepatol; 2016; 10(2):229-42. PubMed ID: 26641143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review article: new treatments in non-alcoholic fatty liver disease.
    Townsend SA; Newsome PN
    Aliment Pharmacol Ther; 2017 Sep; 46(5):494-507. PubMed ID: 28677333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Future trends in the treatment of non-alcoholic steatohepatitis.
    Fiorucci S; Biagioli M; Distrutti E
    Pharmacol Res; 2018 Aug; 134():289-298. PubMed ID: 30021122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preventing liver fibrosis in patients with NAFLD and the road ahead.
    Nobili V; Miele L; Alisi A
    Expert Rev Gastroenterol Hepatol; 2017 Dec; 11(12):1081-1083. PubMed ID: 28994314
    [No Abstract]   [Full Text] [Related]  

  • 25. Role of cenicriviroc in the management of nonalcoholic fatty liver disease.
    Neokosmidis G; Tziomalos K
    World J Gastroenterol; 2018 Dec; 24(48):5415-5417. PubMed ID: 30622370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Grape Leucoanthocyanidin Protects Liver Tissue in Albino Rabbits with Nonalcoholic Hepatic Steatosis.
    Franklin R; Bispo RFM; Sousa-Rodrigues CF; Pires LAS; Fonseca A; Babinski MA
    Cells Tissues Organs; 2018; 205(3):129-136. PubMed ID: 29913455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice.
    Onoyama T; Koda M; Okamoto T; Kishina M; Matono T; Sugihara T; Murawaki Y
    Mol Med Rep; 2015 Nov; 12(5):6895-902. PubMed ID: 26397061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The novel intracellular protein CREG inhibits hepatic steatosis, obesity, and insulin resistance.
    Zhang QY; Zhao LP; Tian XX; Yan CH; Li Y; Liu YX; Wang PX; Zhang XJ; Han YL
    Hepatology; 2017 Sep; 66(3):834-854. PubMed ID: 28508477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis.
    Lee DH; Han DH; Nam KT; Park JS; Kim SH; Lee M; Kim G; Min BS; Cha BS; Lee YS; Sung SH; Jeong H; Ji HW; Lee MJ; Lee JS; Lee HY; Chun Y; Kim J; Komatsu M; Lee YH; Bae SH
    Free Radic Biol Med; 2016 Oct; 99():520-532. PubMed ID: 27634173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fenofibrate treatment attenuated chronic endoplasmic reticulum stress in the liver of nonalcoholic fatty liver disease mice.
    Zhang N; Lu Y; Shen X; Bao Y; Cheng J; Chen L; Li B; Zhang Q
    Pharmacology; 2015; 95(3-4):173-80. PubMed ID: 25896720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Research progress on therapeutic targets of active components in Chinese herbs for treatment of nonalcoholic fatty liver disease].
    Pan YT; Xu FY; Yu XZ; Shang WB
    Zhongguo Zhong Yao Za Zhi; 2017 Mar; 42(6):1109-1112. PubMed ID: 29027424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alisol A 24-acetate ameliorates nonalcoholic steatohepatitis by inhibiting oxidative stress and stimulating autophagy through the AMPK/mTOR pathway.
    Wu C; Jing M; Yang L; Jin L; Ding Y; Lu J; Cao Q; Jiang Y
    Chem Biol Interact; 2018 Aug; 291():111-119. PubMed ID: 29883724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mitochondrial aldehyde dehydrogenase activation by Alda-1 inhibits atherosclerosis and attenuates hepatic steatosis in apolipoprotein E-knockout mice.
    Stachowicz A; Olszanecki R; Suski M; Wiśniewska A; Totoń-Żurańska J; Madej J; Jawień J; Białas M; Okoń K; Gajda M; Głombik K; Basta-Kaim A; Korbut R
    J Am Heart Assoc; 2014 Nov; 3(6):e001329. PubMed ID: 25392542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
    Nakatsu Y; Seno Y; Kushiyama A; Sakoda H; Fujishiro M; Katasako A; Mori K; Matsunaga Y; Fukushima T; Kanaoka R; Yamamotoya T; Kamata H; Asano T
    Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(1):G42-51. PubMed ID: 25999428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Attenuation of hepatic steatosis by purple sweet potato colour is associated with blocking Src/ERK/C/EBPβ signalling in high-fat-diet-treated mice.
    Wang X; Zhang ZF; Zheng GH; Wang AM; Sun CH; Qin SP; Zhuang J; Lu J; Ma DF; Zheng YL
    Appl Physiol Nutr Metab; 2017 Oct; 42(10):1082-1091. PubMed ID: 28636830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.
    Faghihzadeh F; Adibi P; Rafiei R; Hekmatdoost A
    Nutr Res; 2014 Oct; 34(10):837-43. PubMed ID: 25311610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Osteocalcin improves nonalcoholic fatty liver disease in mice through activation of Nrf2 and inhibition of JNK.
    Du J; Zhang M; Lu J; Zhang X; Xiong Q; Xu Y; Bao Y; Jia W
    Endocrine; 2016 Sep; 53(3):701-9. PubMed ID: 26994931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Ethanol Extract from Lonicera japonica Thunb. Regresses Nonalcoholic Steatohepatitis in a Methionine- and Choline-Deficient Diet-Fed Animal Model.
    Tzeng TF; Tzeng YC; Cheng YJ; Liou SS; Liu IM
    Nutrients; 2015 Oct; 7(10):8670-84. PubMed ID: 26506376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exendin‑4, a glucagon‑like peptide‑1 receptor agonist, modulates hepatic fatty acid composition and Δ‑5‑desaturase index in a murine model of non‑alcoholic steatohepatitis.
    Kawaguchi T; Itou M; Taniguchi E; Sata M
    Int J Mol Med; 2014 Sep; 34(3):782-7. PubMed ID: 24993337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.